Kuala Lumpur, Malaysia The company was established in Asia in Malaysia. The leading representative office of defined Corporate Investor is situated in the Kuala Lumpur.
The standard case for the fund is to invest in rounds with 1-2 partakers. Despite the Genting Berhad, startups are often financed by Vulcan Capital, Domain Associates. The meaningful sponsors for the fund in investment in the same round are Vulcan Capital, Domain Associates.
Considering the real fund results, this Corporate Investor is 80 percentage points more often commits exit comparing to other organizations. The common things for fund are deals in the range of 10 - 50 millions dollars. The fund is generally included in less than 2 deals every year. The top activity for fund was in 2013.
Among the most popular fund investment industries, there are Health Care, Biotechnology. Besides, a startup requires to be at the age of 6-10 years to receive the investment from the fund. Among the most popular portfolio startups of the fund, we may highlight Applied Proteomics. For fund there is no match between the country of its foundation and the country of its the most frequent investments - United States.
| Fund Name | Location |
| Ampega Asset Management | - |
| Angel | - |
| Committed Capital | Amsterdam, Noord-Holland, The Netherlands |
| Exhilarator | District of Columbia, United States, Washington |
| Foxmont Capital Partners | Manila, Philippines |
| IDFC SPICE Fund | India, Maharashtra, Mumbai |
| Morgan Holland Ventures | - |
| MS Pace LP | - |
| RBS Investment Group | Canada, Ontario, Toronto |
| Verge HealthTech Fund | Central, Central Region, Singapore |
Notable deals
| Company | Industry | Round Size | Date | Investors | Location |
Fasal | $4M | 16 Nov 2021 | Bengaluru, Karnataka, India | ||
Nova Satra Dx | $2M | 04 Apr 2017 | Singapore, Central Region, Singapore | ||
| 28 Apr 2014 | London, England, United Kingdom | ||||
Applied Proteomics | $28M | 20 Aug 2013 | San Diego, California, United States |
1. You post comments at your own choice and risk. You bear the whole responsibility,related to their substance, content and the fact of publication. We shall not bear anyliability in respect of such comments.
2. While commenting, you shall use only actual, truthful and confirmed data. In thesame time you shall not use vulgar, abusive or defamatory language as well as expresshatred or call to violence or cruelty.
3. We do not intend to delete any comments on the website unless within our “noticeand take down” procedure.
4. We can moderate comments at any time.
5. While commenting, you are under the rule of our website’s terms of use and privacypolicy.
6. We retain our right to delete any comment or any other content of the website at ourwill in case we know or suppose such content is illegal or breaches any lawful right.
Review
- No reviews are submitted yet.
Sign up and get access to full fund profile and advanced analysis.
Full teamIndustries heatmapStages heatmapGeorgaphy breakdownCoinvestorsPortfolio analysisPerformance indexesLatest highlights
Unlock all data Latest deals
| Company | Industry | Round Size | Date | Investors | Location |
Fasal | $4M | 16 Nov 2021 | Bengaluru, Karnataka, India | ||
Nova Satra Dx | $2M | 04 Apr 2017 | Singapore, Central Region, Singapore | ||
| 28 Apr 2014 | London, England, United Kingdom | ||||
Applied Proteomics | $28M | 20 Aug 2013 | San Diego, California, United States |
